Optimi To Supply Psilocybin For New Zealand’s Mātai Medical Research Institute
Canadian licensed psychedelics pharmaceutical manufacturer Optimi Health Corp. (OTCQX:OPTHF) has signed an international agreement to supply natural psilocybin to New Zealand-based Mātai Medical Research Institute, on behalf of the Tū Wairua Project.
The agreement marks Optimi’s first supply deal involving Kiwiland, and “a significant milestone” for the company’s global expansion efforts.
The company will provide Mātai with its GMP Full Spectrum Natural Psilocybin extract, and further track stability of the extract toward ensuring the highest standards of GMP quality and compliance.
Join us at our upcoming Benzinga Cannabis Capital Conference!
Zealand Endeavor
November 2023, the individuals, whānau (families), community groups and institutions that make up the Tū Wairua project gathered at Rangiwaho Marae, a tribal meeting place in New Zealand’s Tairāwhiti region.
The project team has since designed a clinical …